JP2022527025A - 神経変性疾患及びミトコンドリア病の治療のための組成物及びその使用方法 - Google Patents

神経変性疾患及びミトコンドリア病の治療のための組成物及びその使用方法 Download PDF

Info

Publication number
JP2022527025A
JP2022527025A JP2021560413A JP2021560413A JP2022527025A JP 2022527025 A JP2022527025 A JP 2022527025A JP 2021560413 A JP2021560413 A JP 2021560413A JP 2021560413 A JP2021560413 A JP 2021560413A JP 2022527025 A JP2022527025 A JP 2022527025A
Authority
JP
Japan
Prior art keywords
alkyl
membered
present
formula
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021560413A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527025A5 (enExample
Inventor
ルーレ ダニエル ドゥ
ヨハン バルトロメウス
ショーン ジョンストン
ランドール マルセロ チン
ニコラス トーマス ハーツ
ロバート デヴィータ
Original Assignee
ミトキニン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ミトキニン インコーポレイテッド filed Critical ミトキニン インコーポレイテッド
Publication of JP2022527025A publication Critical patent/JP2022527025A/ja
Publication of JP2022527025A5 publication Critical patent/JP2022527025A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021560413A 2019-04-03 2020-04-03 神経変性疾患及びミトコンドリア病の治療のための組成物及びその使用方法 Pending JP2022527025A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962828995P 2019-04-03 2019-04-03
US62/828,995 2019-04-03
US201962879794P 2019-07-29 2019-07-29
US62/879,794 2019-07-29
US201962933632P 2019-11-11 2019-11-11
US62/933,632 2019-11-11
PCT/US2020/026732 WO2020206363A1 (en) 2019-04-03 2020-04-03 Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease

Publications (2)

Publication Number Publication Date
JP2022527025A true JP2022527025A (ja) 2022-05-27
JP2022527025A5 JP2022527025A5 (enExample) 2023-04-17

Family

ID=72666280

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021560413A Pending JP2022527025A (ja) 2019-04-03 2020-04-03 神経変性疾患及びミトコンドリア病の治療のための組成物及びその使用方法

Country Status (11)

Country Link
US (2) US20220162215A1 (enExample)
EP (1) EP3947390A4 (enExample)
JP (1) JP2022527025A (enExample)
KR (1) KR20220004068A (enExample)
CN (1) CN114026093A (enExample)
AU (1) AU2020253561A1 (enExample)
BR (1) BR112021019802A2 (enExample)
CA (1) CA3135755A1 (enExample)
IL (1) IL286767A (enExample)
MX (1) MX2021012129A (enExample)
WO (1) WO2020206363A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026512555A (ja) * 2024-03-22 2026-04-17 誠達薬業股▲ふん▼有限公司 ４－クロロピロロピリミジンアナログ化合物またはその派生物の合成方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018237145A1 (en) 2017-06-21 2018-12-27 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
WO2023023671A1 (en) * 2021-08-20 2023-02-23 Mitokinin, Inc. Compositions and methods for treatment of neurodegenerative and mitochondrial disease
WO2023023670A1 (en) * 2021-08-20 2023-02-23 Mitokinin, Inc. Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
WO2024040266A2 (en) * 2022-08-19 2024-02-22 Mitokinin, Inc. Disubstituted benzoimidazole and indole analogs as modulators of pink1
EP4620957A1 (en) * 2024-03-22 2025-09-24 Eberhard Karls Universität Tübingen Imidazo[4,5-b]pyridin-7-amine compounds binding aurora kinase a and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11511761A (ja) * 1996-06-21 1999-10-12 フアルマシア・エ・アツプジヨン・エツセ・ピー・アー チロシンキナーゼ抑制剤としての２環式４−アラルキルアミノピリミジン誘導体
WO2014124458A1 (en) * 2013-02-11 2014-08-14 The Regents Of The University Of California Compositions and methods for treating neurodegenerative diseases
US20170190704A1 (en) * 2014-02-11 2017-07-06 Mitokinin, LLC Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
WO2018106818A1 (en) * 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
WO2018237145A1 (en) * 2017-06-21 2018-12-27 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101316853B (zh) * 2005-08-04 2014-09-24 西特里斯药业公司 作为sirtuin调节剂的苯并噻唑和噻唑并吡啶
ES2412384T3 (es) * 2006-07-18 2013-07-11 Astellas Pharma Inc. Derivado de aminoindano o sal del mismo
EP2818472A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators
CN108934162A (zh) * 2015-12-16 2018-12-04 南方研究所 吡咯并嘧啶化合物、作为激酶lrrk2抑制剂的用途及其制备方法
WO2018065365A1 (en) * 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
KR20220158290A (ko) * 2020-02-21 2022-11-30 미토키닌, 인크. 신경퇴행성 및 미토콘드리아 질환의 치료를 위한 조성물 및 이를 사용하는 방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11511761A (ja) * 1996-06-21 1999-10-12 フアルマシア・エ・アツプジヨン・エツセ・ピー・アー チロシンキナーゼ抑制剤としての２環式４−アラルキルアミノピリミジン誘導体
WO2014124458A1 (en) * 2013-02-11 2014-08-14 The Regents Of The University Of California Compositions and methods for treating neurodegenerative diseases
US20170190704A1 (en) * 2014-02-11 2017-07-06 Mitokinin, LLC Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
WO2018106818A1 (en) * 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
WO2018237145A1 (en) * 2017-06-21 2018-12-27 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REGISTRY（STN）[ONLINE], JPN7024001109, ISSN: 0005442415 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026512555A (ja) * 2024-03-22 2026-04-17 誠達薬業股▲ふん▼有限公司 ４－クロロピロロピリミジンアナログ化合物またはその派生物の合成方法

Also Published As

Publication number Publication date
WO2020206363A1 (en) 2020-10-08
EP3947390A1 (en) 2022-02-09
MX2021012129A (es) 2022-01-31
US20220162215A1 (en) 2022-05-26
CN114026093A (zh) 2022-02-08
IL286767A (en) 2021-12-01
KR20220004068A (ko) 2022-01-11
CA3135755A1 (en) 2020-10-08
AU2020253561A1 (en) 2021-12-02
US20250250276A1 (en) 2025-08-07
EP3947390A4 (en) 2022-11-30
BR112021019802A2 (pt) 2021-12-07

Similar Documents

Publication Publication Date Title
US20250250276A1 (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
KR101965025B1 (ko) 피라졸로[1,5-a]피리미딘계 화합물, 그를 포함하는 조성물 및 그의 사용 방법
CN113631557A (zh) Jak激酶抑制剂及其制备方法和在医药领域的应用
US10112922B2 (en) Inhibitor of bruton's tyrosine kinase
WO2025011568A1 (zh) 用作shp2抑制剂的杂环化合物、包含其的药物组合物及其制备方法和用途
US20210130352A1 (en) Oga inhibitor compounds
JP6851825B2 (ja) 非アポトーシス性の制御された細胞死の阻害剤としてのスピロキノキサリン誘導体
JP2016500119A (ja) ブルトン型チロシンキナーゼ阻害剤
JP6708849B1 (ja) ピロロピリジン誘導体化合物、その製造方法及びこれを有効成分として含有するタンパク質キナーゼ関連疾患の予防または治療のための薬学的組成物
CN107849036A (zh) 二环化合物
JP7808226B2 (ja) 神経変性疾患及びミトコンドリア病の治療用の組成物ならびにその使用方法
US11858938B2 (en) Imidazo-fused heterocycles and uses thereof
EP4155294A1 (en) Compound for preventing or treating lipid metabolism-related diseases
WO2019057112A1 (zh) 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用
TW202416989A (zh) 作為pi3k抑制劑的苯并嘧啶-4(3h)-酮
KR20190025545A (ko) 특정 단백질 키나제 억제제
US20250161319A1 (en) Use of hpk1 inhibitor in treatment of interferon-related diseases
TW201823222A (zh) 化合物、醫藥組成物及其用途
WO2021149767A1 (ja) ヘテロ環誘導体
US20250129080A1 (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
CN108658976B (zh) 一类新型吡唑并[4,3-c]吡啶-4(5)-酮布鲁顿激酶抑制剂
US20240376111A1 (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
WO2024040266A2 (en) Disubstituted benzoimidazole and indole analogs as modulators of pink1
BR122025016812A2 (pt) Compostos de adeninas, uso dos mesmos, composição farmacêutica, método para modular a atividade da quinase pink1 em um indivíduo, e kit
HK40086209B (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230403

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231027

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240319

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240618

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241022